Apogee Therapeutics (APGE) Expected to Announce Earnings on Monday

Apogee Therapeutics (NASDAQ:APGE) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Apogee Therapeutics to post earnings of ($1.19) per share for the quarter.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.25). On average, analysts expect Apogee Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Apogee Therapeutics Trading Down 1.4 %

NASDAQ APGE opened at $37.29 on Friday. The company has a 50-day moving average price of $36.26 and a two-hundred day moving average price of $41.65. Apogee Therapeutics has a 52 week low of $26.20 and a 52 week high of $63.50. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -15.41 and a beta of 1.70.

Analyst Ratings Changes

A number of brokerages recently issued reports on APGE. Citigroup initiated coverage on Apogee Therapeutics in a report on Thursday, March 13th. They issued a “buy” rating and a $95.00 price objective for the company. Wedbush reissued an “outperform” rating and issued a $90.00 price target on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Finally, Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Apogee Therapeutics presently has an average rating of “Buy” and an average target price of $92.17.

Insider Activity

In other news, insider Carl Dambkowski sold 3,860 shares of the business’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $36.22, for a total transaction of $139,809.20. Following the sale, the insider now owns 247,173 shares in the company, valued at $8,952,606.06. The trade was a 1.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Thomas Henderson sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total transaction of $301,500.00. Following the completion of the sale, the chief executive officer now owns 1,292,987 shares of the company’s stock, valued at approximately $38,983,558.05. This trade represents a 0.77 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,175 shares of company stock worth $587,191. 36.10% of the stock is owned by company insiders.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.